These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34896803)

  • 1. Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer.
    Bryant AK; Sankar K; Strohbehn GW; Zhao L; Elliott D; Qin A; Yentz S; Ramnath N; Green MD
    Lung Cancer; 2022 Jan; 163():35-41. PubMed ID: 34896803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab.
    Bryant AK; Sankar K; Strohbehn GW; Zhao L; Daniel V; Elliott D; Ramnath N; Green MD
    Int J Radiat Oncol Biol Phys; 2022 Jul; 113(4):752-758. PubMed ID: 35450753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
    Scilla KA; Bentzen SM; Lam VK; Mohindra P; Nichols EM; Vyfhuis MA; Bhooshan N; Feigenberg SJ; Edelman MJ; Feliciano JL
    Oncologist; 2017 Jun; 22(6):737-742. PubMed ID: 28533476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy.
    Palomar-Abril V; Soria-Comes T; Campos ST; Ureste MM; Bosch VG; Maiques ICM
    Clin Transl Oncol; 2020 Dec; 22(12):2333-2340. PubMed ID: 32449125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis.
    Platini H; Ferdinand E; Kohar K; Prayogo SA; Amirah S; Komariah M; Maulana S
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated neutrophil-to-lymphocyte ratio (NLR) is associated with poorer progression-free survival in unresectable stage III NSCLC treated with consolidation durvalumab.
    Nindra U; Shahnam A; Stevens S; Pal A; Nagrial A; Lee J; Yip PY; Adam T; Boyer M; Kao S; Bray V
    Thorac Cancer; 2022 Nov; 13(21):3058-3062. PubMed ID: 36111516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Who Benefits the Most From Adjuvant Durvalumab After Chemoradiotherapy for Non-small Cell Lung Cancer? An Exploratory Analysis.
    Ohri N; Halmos B; Bodner WR; Cheng H; Garg MK; Gucalp R; Guha C
    Pract Radiat Oncol; 2021; 11(2):e172-e179. PubMed ID: 33127337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone.
    Saad A; Goldstein J; Appel S; Daher S; Urban D; Onn A; Gantz-Sorotsky H; Lobachov A; Gottfried T; Spieler B; Bar J
    Thorac Cancer; 2022 Jun; 13(12):1763-1771. PubMed ID: 35538909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 11. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
    Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA
    Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study.
    Trinh JQ; Xiong Y; Smith LM; Abughanimeh O; Marr AS; Ganti AK
    Anticancer Res; 2024 Feb; 44(2):605-612. PubMed ID: 38307589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Jiang T; Bai Y; Zhou F; Li W; Gao G; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2019 Apr; 130():76-83. PubMed ID: 30885355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.
    Chu CH; Chiu TH; Wang CC; Chang WC; Huang AC; Liu CY; Wang CL; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
    Thorac Cancer; 2020 Jun; 11(6):1541-1549. PubMed ID: 32281272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer.
    Matsuura S; Serizawa S; Yamashita R; Morikawa K; Ito Y; Hiramatsu T; Mochizuki E; Tanaka K; Akiyama N; Tsukui M; Koshimizu N; Kosugi T
    Ann Med; 2023 Dec; 55(1):2196089. PubMed ID: 37043179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer.
    Bryant AK; Sankar K; Zhao L; Strohbehn GW; Elliott D; Moghanaki D; Kelley MJ; Ramnath N; Green MD
    Eur J Cancer; 2022 Aug; 171():55-63. PubMed ID: 35704975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic implications of neutrophil-to-lymphocyte ratio in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy: A multicenter, real-world study.
    Bi H; Ren D; Xiao Y; Zhou Y; Yi B; Han W; Shao Y; Wang J; Zhang C; Wang H
    Thorac Cancer; 2024 Mar; 15(7):559-569. PubMed ID: 38294282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.